Category Archives: Science & Technology

Jokowi condoles deaths of medical workers from COVID-19

Jakarta (ANTARA) – President Joko Widodo (Jokowi) expressed deep condolences to the families of doctors and paramedics, who died from COVID-19.

“I want to express my deep condolences on the demise of doctors, nurses, and other paramedics,” Jokowi stated during his visit to the Athletes Village in Kemayoran, Jakarta, on Monday.

The Athletes Village has been readied to function as a temporary hospital to treat COVID-19 patients.

“They are dedicated (medical workers), who have fought hard to handle the coronavirus outbreak. On behalf of the government, country, and people, I laud their hard work and struggle to handle COVID-19,” the president noted.

The Indonesian Doctors Association (IDI) had earlier confirmed that its six members had died from COVID-19. It said those doctors had contracted the infection while performing their duties to treat COVID-19 patients.

Source: ANTARA News

Daarut Tauhid Islamic boarding school closed anticipating COVID-19

In optimizing our endeavor to prevent the spread of this virus, Daarut Tauhid has decided to terminate the teaching and learning activities at the boarding school

Bandung, W Java (ANTARA) – The leader of Daarut Tauhid Islamic Boarding School, Abdullah Gymnastiar (Aa Gym), has shut the school anticipating the spread of novel coronavirus (COVID-19) as the Indonesian Government strives to handle the rising number of patients. “In optimizing our endeavor to prevent the spread of this virus, Daarut Tauhid has decided to terminate the teaching and learning activities at the boarding school,” he said on his social media account that ANTARA observed here Saturday.

Despite the temporary closure of the Islamic boarding school, located at Geger Kalong area of Bandung, the capital of West Java Province, Aa Gym urged the boarding school’s santris (students) to keep studying at home during the 14-day closure.

This respected ulema also revealed that massive gatherings at Daarut Tauhid would also be terminated for the time being. Instead, the activities would be focused on cleaning the area to stop the potential spread of this new coronavirus.

For Indonesian Muslims, Aa Gym called on them to increase the quality of their shalat (prayers), zikir (chants praising God), and sadaqah (charity). At the same time, they are also urged to follow the latest information on the virus.

“Do not panic. Please remain calm, and do not overreact that may make us stressful. Instead, please do not also downplay and ignore,” he added.

In another development, the number of COVID-19 patients in Indonesia has jumped to 96, as the virus has spread to several regions, including Jakarta, Bandung, Tangerang, Solo, Yogyakarta, Bali, Manado, and Pontianak.

“According to today’s update, the number of confirmed cases has reached 96 after yesterday, we had 69 cases. There are 27 new cases,” Achmad Yurianto, a spokesman for coronavirus handling, said.

The new cases came to light after the government conducted massive contact tracing, he revealed.

So far, five coronavirus patients have died, of which four — case 25, 35, 36, and case 50 — were linked to the initial 69 cases.

On Saturday morning, the World Dream’s 188 crew members had departed from the Sebaru Kecil Island, part of Jakarta, because they had completed their 14-day quarantine.

They boarded the Indonesian Naval Ship KRI-Semarang 594 to the pier of the Military Naval Command (Kolinlamil) in Tanjung Priok, North Jakarta. At the pier, the crew members were received by representatives of their regional administrations.

One of the World Dream cruise ship’s crew members named Vidya told journalists that “being passionate about staying healthy” has become the motto for her and her colleagues during their stay in Jakarta’s small island.

“What is important for us during the observation period is that we have the passion to stay healthy and keep clean,” said the 40-year-old woman.

The government provided Vidya and her colleagues with buses to take them to destinations such as the Halim Perdanakusuma Airport and Soekarno Hatta International Airport since several of them would depart for their hometowns Saturday afternoon and evening.

Several others were dropped off at hotels or homes of relatives while awaiting departure for their homes, he stated, adding that he did not wish to divulge the names crew members and addresses of the homes of their families or hotels where they are staying in Jakarta.

Source: ANTARA News

Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine

EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland (UQ) as part of a Coalition for Epidemic Preparedness (CEPI) initiative to develop a vaccine to prevent COVID-19.  Dynavax is providing technical expertise and the Company’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.

CpG 1018 is the adjuvant used in HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA). Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B. CpG 1018 provides a well‑developed technology and a significant safety database, potentially accelerating the development of a COVID-19 vaccine.

CEPI, in conjunction with the World Health Organization, is leading multiple programs/partnerships that seek to improve the scientific understanding of the novel coronavirus, and to develop vaccines against it. UQ and CEPI established a partnership in January 2019 focused on developing a “molecular clamp” vaccine platform, a technology that enables targeted and rapid vaccine production against multiple viral pathogens.  Building on this existing partnership, CEPI requested UQ use its recently developed rapid response technology, which allows for the rapid generation of new vaccines from the knowledge of a virus’s genetic sequence information, to develop a new vaccine against COVID-19.

“The comprehensive humanitarian response to address the risk of COVID-19 by the vaccine development community is a testament to the dedication our industry has to global public health,” commented Ryan Spencer, Chief Executive Officer of Dynavax. “We are proud to contribute to this global effort to develop a vaccine to prevent COVID-19 in collaboration with the exceptional team of researchers at the University of Queensland.”

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.  For more information, visit and follow the company on LinkedIn.

About University of Queensland
The University of Queensland is one of Australia’s leading research and teaching institutions, a global top 50 university, ranked first in Australia and ninth in the world for biotechnology.

About Coalition for Epidemic Preparedness Innovations (CEPI)
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (ie, Disease X). To date, CEPI has committed to investing over $475 million in vaccine and platform development.  Learn more at Follow us at @CEPIvaccines.

Forward-Looking Statements
This press release contains “forward-looking” statements, including statements regarding the potential to develop a COVID-19 vaccine and to do so on an accelerated basis.  Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in vaccine research and development, including the timing of completing development, the results of clinical trials, and whether and when the vaccine will be approved for use, as well as other risks detailed in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax’s website at is not incorporated by reference in our current periodic reports with the SEC.

Nicole Arndt, Senior Manager, Investor Relations

Derek Cole, President
Investor Relations Advisory Solutions

Ascom Myco 3 smartphone gets certification from MEDITECH for the Expanse Point of Care EHR Solution

Ascom announced that EHR provider MEDITECH has certified the Ascom Myco 3 smartphone with its Expanse Point of Care solution. Nurses, therapists, aides, and other clinicians can now complete most tasks on their handheld Ascom Myco 3 device – including receive alerts, document vitals and interventions, review records, and verify and administer medications using the smartphone’s built-in barcode scanner. Patients can also benefit from more quality caregiving time with their clinicians.

MEDITECH joins an increasing roster of prominent EHR companies to certify the healthcare device on its platform to meet the communication needs of medical organizations today and tomorrow.

Pamela Crandall, Senior Marketing Solution Manager at MEDITECH, says: “The Ascom Myco 3 device gives our customers another powerful option for accessing our Expanse Point of Care and wireless phlebotomy solutions through Dryrain’s Enterprise browser. Nurses appreciate the mobility of using smartphone devices and the additional facetime it gives them with patients.”

Phlebotomists can also use the Ascom Myco 3 to access MEDITECH’s phlebotomy handheld solution to access a real-time list of specimens awaiting collection and print labels at the patient’s bedside. In addition, phlebotomists can use the barcode scanner to verify patient identification prior to specimen draw.

Francis Schmeer, Chief Sales Officer of Ascom, underlines: “We are delighted to partner with MEDITECH, a leading vendor and founder of the EHR market. The Ascom Myco 3, sold globally and in trials in many leading hospitals, is showing great results across the care continuum. Our aim with this smartphone designed for healthcare professionals is to provide mobility with confidence and improve clinician workflows at the point of care.”

For more information on the Ascom Myco 3 smartphone visit the website here.

Philips sleep survey shows only half of people worldwide are satisfied with their sleep, but are less likely than before to take action to improve it

March 2, 2020

  • Global survey reveals 36% have slept separately from their bed partner in an attempt to improve sleep
  • 74% admit to using cell phones in bed
  • 60% agree they are interested in new information or strategies to help them get better sleep

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the findings from its 5th annual sleep survey in a report, “Wake Up Call: Global Sleep Satisfaction Trends.” Philips surveyed more than 13,000 adults in 13 countries to capture attitudes, perceptions, and behaviors around sleep. This year’s results show global sleep satisfaction remains low with worry/stress, relationships and cell phone use reported as key sleep inhibitors.

Worry and stress continue to affect a good night’s sleep
Only 49% of people are satisfied [1] with their sleep, with worry/stress reported as the most limiting factor to a good night’s sleep (33%). Interestingly, fewer people in 2020 are taking action to improve sleep compared to 2019, with nearly all listed strategies to improve sleep lower or consistent in 2020 when compared to 2019 results. For example, reading before bed was the most popular strategy used to improve sleep in 2019 (39%), but only 28% of people report reading to improve sleep in 2020. Other notable distinctions in sleep-related behavior appeared across age and gender differences.

“The decrease in people taking action to improve sleep is alarming, especially when it is clear people around the world deeply value sleep. Sleep deficit impacts people both mentally and physically, so we need to educate people on available sleep resources and empower them with the confidence that their efforts will pay off,” said Mark Aloia, PhD, Global Lead for Behavior Change, Sleep & Respiratory Care at Philips. “As we head into the next decade, Philips is focused on designing a future where technology leveraged across the entire sleep ecosystem can help people get the most out of their lives.”

Sleep issues coming between bedpartners
Factors putting quality sleep at risk stem from both social and technology distractions. When it comes to relationships, 36% of people with a partner/spouse agree [1] they sometimes sleep separately from their partner/spouse to improve their sleep, and 30% agree [1] their or their partner/spouse’s difficulty sleeping is impacting their relationship. Despite experts’ recommendations to the contrary, almost 4-in-ten report using their phones right before falling asleep (39%) or as soon as they wake up (39%).

While external factors can be altered to improve sleep, some sleep conditions are outside of a person’s control. This year, respondents report lower rates of insomnia, snoring, shift work disorder and chronic pain, but sleep apnea remains consistent (2019: 10% vs. 2020: 9%). Of those reporting to have sleep apnea, 51% said their sleep apnea is impacting their relationship(s). Yet, 48% of people with sleep apnea said they felt getting good sleep was out of their control – even though a variety of solutions exist to treat it.

The desire for help is there, as 60% of people agree [1] they are interested in new information or strategies to help them get better sleep. Watching TV remains the most common strategy people use to improve their sleep (2019: 37% vs. 2020: 33%), and new data this year shows 15% have tried or currently use either marijuana or CBD oil to better their sleep. For more insight from this year or past years’ surveys, please visit

Using 35 years of deep clinical expertise in sleep technology, Philips’ growing portfolio of sleep solutions seek to address 80% of the most common sleep issues [2]. To learn more about the Global Sleep Survey and Philips’ commitment to improving access to sleep technology worldwide, visit To join the conversation about sleep health and Philips’ growing suite of consumer and scripted sleep solutions, follow @Philips@PhilipsSleepWellness or @PhilipsResp.

[1] indicates net “somewhat” or “complete” agreement with the statement
[2] Snoring, Short Sleep, Insomnia, and Obstructive Sleep Apnea

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
Twitter: kathyoreilly

Meredith Amoroso
Philips Sleep and Respiratory Care
Mobile: +1 724-584-8991

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at

About the Survey
This survey was conducted online by KJT Group, Inc. on behalf of Philips from November 12 – December 5, 2019 among 13,004 adults ages 18 and older in 13 countries (Australia: n=1,000; Brazil: n=1,000; China: n=1,001; France: n=1,000; Germany: n=1,000; India: n=1,000; Italy: n=1,000; Japan: n=1,001; Netherlands: n=1,001; Singapore: n=1,000; South Korea: n=1,000; United Kingdom: n=1,000; and the U.S.: n=1,001). The survey was web-based and self-administered in the primary language(s) of each country. These were non-probability samples and thus a margin of error cannot be accurately estimated. For complete survey methodology, including weighting variables, please contact Meredith Amoroso at